KADCYLA side effects and safety profile

The most common Grade ≥3 adverse reactions (ARs) (>2%) in the KATHERINE trial were thrombocytopenia and hypertension.

ARs occurring in ≥10% of patients in the KATHERINE trial1

*Included one fatal hemorrhage.

The following clinically relevant ARs were reported in <10% of patients in the KADCYLA-treated group in KATHERINE: blood alkaline phosphatase increased (8%), dysgeusia (8%), dyspnea (8%), neutropenia (8%), blood bilirubin increased (7%), hypokalemia (7%), pruritus (7%), hypertension (6%), lacrimation increased (6%), chills (5%), dry eye (4.5%), dyspepsia (4.3%), peripheral edema (3.9%), vision blurred (3.9%), conjunctivitis (3.5%), left ventricular dysfunction (3.0%), drug hypersensitivity (2.7%), infusion-related reaction (1.6%), radiation pneumonitis (1.5%), pneumonitis (1.1%), rash (1.1%), asthenia (0.4%), nodular regenerative hyperplasia (0.3%).1

Dosing for KADCYLA in EBC

See the efficacy results